484 related articles for article (PubMed ID: 24437955)
1. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V
Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
[TBL] [Abstract][Full Text] [Related]
2. [Ranibizumab in the ARMD wet form of age-related macular degeneration treatment - two years results obtained from the AMADEuS Registry].
Matušková V; Kolář P; Vysloužilová D; Vlková E; Dušek L; Kandrnal V; Jarkovský J; Uher M
Cesk Slov Oftalmol; 2012 Nov; 68(5):171-7. PubMed ID: 23461368
[TBL] [Abstract][Full Text] [Related]
3. Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech Republic.
Stepanov A; Nemcansky J; Veith M; Manethova K; Stredova M; Pencak M; Tarkova A; Studnicka J
Eur J Ophthalmol; 2021 Sep; 31(5):2488-2495. PubMed ID: 33198503
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
[TBL] [Abstract][Full Text] [Related]
6. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
7. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
[TBL] [Abstract][Full Text] [Related]
8. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
10. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
11. [Optical Coherence Tomography Angiography-based Follow-up Observation of Wet Age-related Macular Degeneration after Intravitreal Anti-Ranibizumab Therapy].
Yuan MZ; Zhou HY; Chen YX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Jun; 41(3):359-366. PubMed ID: 31282330
[TBL] [Abstract][Full Text] [Related]
12. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
Lee JY; Chung H; Kim HC
Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
[TBL] [Abstract][Full Text] [Related]
13. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
14. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
Bloch SB; Lund-Andersen H; Sander B; Larsen M
Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
[TBL] [Abstract][Full Text] [Related]
15. [The effect comparison of ranibizumab and sodium pegaptanib on the retinal pigment epithelium ablation size in the treatment of age-related macular degeneration].
Sin M; Jakubcová M; Chrapek O; Pracharová Z; Simicák J; Rehák J
Cesk Slov Oftalmol; 2012 May; 68(2):57-60. PubMed ID: 22913867
[TBL] [Abstract][Full Text] [Related]
16. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
Lala C; Framme C; Wolf-Schnurrbusch UE; Wolf S
Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
[TBL] [Abstract][Full Text] [Related]
17. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
[TBL] [Abstract][Full Text] [Related]
20. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
Jackson TL; Dugel PU; Bebchuk JD; Smith KR; Petrarca R; Slakter JS; Jaffe GJ; Nau JA;
Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
